(Q35573929)

8 August 2017

1 reference

title

Primary biliary cirrhosis: specific treatment (English)

1 reference

primary biliary cholangitis

8 August 2017

main subject

0 references

clinical trial

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594138

27 March 2024

author name string

Robert L. Carithers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594138

27 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14594138

27 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S108932610300103X?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00103-X

https://api.elsevier.com/content/article/PII:S108932610300103X?httpAccept=text/plain

27 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00103-X

27 March 2024

published in

Clinics in liver disease

1 reference

8 August 2017

volume

7

1 reference

8 August 2017

issue

4

1 reference

8 August 2017

page(s)

923-939

1 reference

Is copper hepatotoxic in primary biliary cirrhosis?

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A prospective trial of D-penicillamine in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

D-penicillamine treatment improves survival in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Trial of penicillamine in advanced primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Evaluation of colchicine therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A prospective trial of colchicine for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeoxycholic acid for primary biliary cirrhosis: lesson for the future?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeooxycholic acid for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

URSO-panacea or placebo?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Randomized trial of chlorambucil for primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900103-X

7 January 2021

Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis

29

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00103-X

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

27 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00103-X

The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study

27 March 2024

54

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00103-X

27 March 2024

Identifiers

1 reference

8 August 2017

1 reference